The Platinum Study

The Platinum Study is an R01-funded, multicenter study of testicular cancer survivors that characterizes both long-term cisplatin-induced peripheral neuropathy (CisIPN) and cisplatin-associated ototoxicity, i.e., permanent, bilateral hearing loss. We collected data abstracted from medical records (e.g., cumulative cisplatin dose), conducted audiometric examinations, and administered self-report questionnaires, which included CisIPN symptoms. ]]> Inclusion Criteria: 1. Diagnosis or confirmation of diagnosis (by review) of a histologically or serologically confirmed testicular germ cell tumor (GCT) or GCT at another anatomic location by one of the participating sites. 2. Age at GCT diagnosis is 55 years or younger. 3. Males, 18 years of age or older at time of consent. 4. Willingness to provide consent. 5. Able to speak and read English. 6. Treatment consisted of a cisplatin-based chemotherapy regimen for either initial testicular germ cell tumor (GCT) or subsequent testicular cancer. 7. Chemotherapy completed greater than/equal to 6 months. 8. Subject currently undergoing active follow-up at one of the participating sites. 9. Subject did not require subsequent salvage chemotherapy treatment or bone marrow transplant. 10. Subject had no prior chemotherapy for a different cancer. Exclusion Criteria: Failure to meet all inclusion criteria. ]]>